Olfactory dysfunction among patients with COVID-19
Copyright: © Saudi Medical Journal..
OBJECTIVES: To assess the frequency of olfactory dysfunction (OD) among individuals afflicted with coronavirus disease of 2019 (COVID-19).
METHODS: A comprehensive literature search was carried out across several bibliographical databases (PubMed, Scopus, Google Scholar, and Web of Science) to extract publications in the English language between January 2020 and December 2021 to report the incidence of OD alone or together with gustatory dysfunction (GD) among COVID-19 patients.
RESULTS: Based on eligibility criteria, 84 articles were included from 27 countries, comprising 36,903 patients, of whom 58.1% were females. The generality rates of olfactory impairment alone was 34.60% and in conjunction with GD was 11.36%. Patients with OD were subclassified into various categories, and the prevalence of anosmia was 20.85%, 5.04% for hyposmia, 8.88% for anosmia or hyposmia, 1.84% for parosmia, 0.78% for phantosmia, and 0.02% for hyperosmia, among COVID-19 patients.
CONCLUSION: Clinical features associated with OD, either isolated or in combination with GD, are common in patients with COVID-19 and consider important signs of COVID-19 that may guide clinicians in the early phase of the disease.PROSPERO Reg. No.: 417296.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Saudi medical journal - 44(2023), 11 vom: 03. Nov., Seite 1085-1103 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alkholaiwi, Feras M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anosmia |
|---|
| Anmerkungen: |
Date Completed 07.11.2023 Date Revised 16.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.15537/smj.2023.44.11.20230264 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364182903 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364182903 | ||
| 003 | DE-627 | ||
| 005 | 20231227132638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15537/smj.2023.44.11.20230264 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1229.xml |
| 035 | |a (DE-627)NLM364182903 | ||
| 035 | |a (NLM)37926445 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alkholaiwi, Feras M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Olfactory dysfunction among patients with COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © Saudi Medical Journal. | ||
| 520 | |a OBJECTIVES: To assess the frequency of olfactory dysfunction (OD) among individuals afflicted with coronavirus disease of 2019 (COVID-19) | ||
| 520 | |a METHODS: A comprehensive literature search was carried out across several bibliographical databases (PubMed, Scopus, Google Scholar, and Web of Science) to extract publications in the English language between January 2020 and December 2021 to report the incidence of OD alone or together with gustatory dysfunction (GD) among COVID-19 patients | ||
| 520 | |a RESULTS: Based on eligibility criteria, 84 articles were included from 27 countries, comprising 36,903 patients, of whom 58.1% were females. The generality rates of olfactory impairment alone was 34.60% and in conjunction with GD was 11.36%. Patients with OD were subclassified into various categories, and the prevalence of anosmia was 20.85%, 5.04% for hyposmia, 8.88% for anosmia or hyposmia, 1.84% for parosmia, 0.78% for phantosmia, and 0.02% for hyperosmia, among COVID-19 patients | ||
| 520 | |a CONCLUSION: Clinical features associated with OD, either isolated or in combination with GD, are common in patients with COVID-19 and consider important signs of COVID-19 that may guide clinicians in the early phase of the disease.PROSPERO Reg. No.: 417296 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hyposmia | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a anosmia | |
| 650 | 4 | |a olfactory dysfunction | |
| 700 | 1 | |a Altamimi, Alhanouf F |e verfasserin |4 aut | |
| 700 | 1 | |a Almalki, Hanan H |e verfasserin |4 aut | |
| 700 | 1 | |a Almughaiseeb, Fay A |e verfasserin |4 aut | |
| 700 | 1 | |a Alsubaie, Shoug S |e verfasserin |4 aut | |
| 700 | 1 | |a Alsayahi, Hessah S |e verfasserin |4 aut | |
| 700 | 1 | |a Alhijli, Fras W |e verfasserin |4 aut | |
| 700 | 1 | |a Alobaishi, Reema S |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Alqahtani, Zuhour A |e verfasserin |4 aut | |
| 700 | 1 | |a Alotaibi, Fahad Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Saudi medical journal |d 1993 |g 44(2023), 11 vom: 03. Nov., Seite 1085-1103 |w (DE-627)NLM078848180 |x 1658-3175 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:11 |g day:03 |g month:11 |g pages:1085-1103 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15537/smj.2023.44.11.20230264 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 11 |b 03 |c 11 |h 1085-1103 | ||